These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 28764565)

  • 21. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
    Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
    Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
    Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
    Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience.
    Fallico M; Maugeri A; Lotery A; Longo A; Bonfiglio V; Russo A; Avitabile T; Furino C; Cennamo G; Barchitta M; Agodi A; Marolo P; Ventre L; Caselgrandi P; Reibaldi M
    Sci Rep; 2021 Feb; 11(1):4800. PubMed ID: 33637841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study.
    Ruiz-Moreno JM; Adán A; Lafuente M; Asencio Durán M; Arias Barquet L; García Layana A; Araiz Iribarren J
    Int Ophthalmol; 2023 Dec; 43(12):4639-4649. PubMed ID: 37697082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
    Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
    BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
    Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
    Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluocinolone acetonide for the treatment of diabetic macular edema.
    Haritoglou C; Mayer W; Wolf A
    Expert Rev Clin Pharmacol; 2016; 9(3):367-74. PubMed ID: 26681198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.
    Currie CJ; Holden SE; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):33-43. PubMed ID: 28881150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
    Adams OE; Schechet SA; Hariprasad SM
    Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluocinolone acetonide implantable device for diabetic retinopathy.
    Schwartz SG; Flynn HW
    Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY.
    Ong SS; Walter SD; Chen X; Thomas AS; Finn AP; Fekrat S
    Retin Cases Brief Rep; 2021 May; 15(3):261-265. PubMed ID: 30015770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study.
    Cutino A; Green K; Kendall R; Moore PT; Zachary C
    Am J Manag Care; 2015 Jan; 21(4 Suppl):S63-72. PubMed ID: 25734663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting.
    Elaraoud I; Andreatta W; Kidess A; Bhatnagar A; Tsaloumas M; Quhill F; Yang Y
    BMC Ophthalmol; 2016 Jan; 16():3. PubMed ID: 26728265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ILUVIEN
    Habib MS
    Ther Deliv; 2018 Aug; 9(8):547-556. PubMed ID: 29943691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results.
    Elbarky AM
    Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials.
    Parrish RK; Campochiaro PA; Pearson PA; Green K; Traverso CE;
    Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):426-35. PubMed ID: 27183546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal steroids for macular edema in diabetes.
    Grover D; Li TJ; Chong CC
    Cochrane Database Syst Rev; 2008 Jan; (1):CD005656. PubMed ID: 18254088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
    Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW;
    Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
    Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
    Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
    Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
    BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.